vivoslife.com - VVOS Company Value to Revenue Ratio

Public company logo of Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics (VVOS) possesses significant pricing power driven by its unique mask-free apnea treatment method. The company's price-to-sales ratio reflects the dynamics of this advantage, where the 538.72 level represents the current value. Market capitalization is supported by the sale of proprietary oral systems. Leveraging regulatory approvals, the business is effectively displacing bulky alternatives and steadily expanding its presence within the medical equipment niche.

VVOS Vivos Therapeutics: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

VVOS (Vivos Therapeutics, Inc): analytical breakdowns and indicator data

Fundamental valuation:Vivos Therapeutics VVOS
Mass-produced product of Vivos Therapeutics Inc.

The EV/Sales multiple determines the total value of a business, including net debt, relative to annual sales volume, allowing for an assessment of an asset's market value regardless of its financing structure. The EV/Sales multiple trend for Vivos Therapeutics (VVOS) reflects the capitalization potential of its unique non-invasive sleep apnea treatment technology, confirming the company's fundamental resilience driven by high confidence from the professional medical community.

Competitor analysis for Vivos Therapeutics

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|SI-BONE Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Orthofix Medical OFIX|Bioventus Global (BVS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume KIDS (OrthoPediatrics Inc.)|Enterprise Value-to-Revenue Ratio treace.com|Company Value to Revenue Strata Critical Medical Inc (SRTA)|EV/Sales Multiple CARL|RXST - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio clearpointneuro.com CLPT|STXS: Company Value to Revenue Ratio|STIM: Company Value to Revenue|sightsciences.com - Enterprise Value-to-Revenue Coefficient|Orchestra BioMed Inc. (OBIO) - Enterprise Value-to-Revenue Ratio|Anika (ANIK) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio InspireMD, Inc.|zhjmedical.com (ZJYL) - Total Company Value-to-Revenue Ratio|Company Value to Revenue VANI (Vivani Medical)|EV/Sales Multiple Xtant Medical Holdings, Inc. (XTNT)|Enterprise Value-to-Revenue Ratio NeuroOne Medical Technologies Corporation NMTC|EV/Sales Multiple Modular Medical MODD|MYO: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Envoy Medical, Inc.|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio